CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Consensus Rating of “Moderate Buy” from Brokerages

CytomX Therapeutics, Inc. (NASDAQ:CTMX) has received a consensus rating of “Moderate Buy” from the eight brokerages that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $9.00.

A number of research analysts recently weighed in on CTMX shares. Cantor Fitzgerald raised their price objective on CytomX Therapeutics from $6.00 to $10.00 and gave the company an “overweight” rating in a research report on Wednesday, February 4th. Piper Sandler raised their price target on CytomX Therapeutics from $6.50 to $10.00 and gave the company an “overweight” rating in a report on Tuesday, January 20th. Barclays lifted their price target on CytomX Therapeutics from $8.00 to $10.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 4th. Guggenheim reiterated a “buy” rating and issued a $10.00 price target on shares of CytomX Therapeutics in a research note on Monday. Finally, HC Wainwright raised their price objective on shares of CytomX Therapeutics from $5.00 to $10.00 and gave the company a “buy” rating in a research note on Tuesday, November 11th.

Hedge Funds Weigh In On CytomX Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. Orbimed Advisors LLC purchased a new stake in CytomX Therapeutics during the 2nd quarter valued at $19,208,000. Commodore Capital LP bought a new stake in shares of CytomX Therapeutics in the 2nd quarter worth $17,462,000. Perceptive Advisors LLC purchased a new position in shares of CytomX Therapeutics in the second quarter worth $15,876,000. Franklin Resources Inc. bought a new position in shares of CytomX Therapeutics during the second quarter valued at $13,096,000. Finally, Vivo Capital LLC purchased a new stake in shares of CytomX Therapeutics during the second quarter valued at $13,096,000. 67.77% of the stock is currently owned by hedge funds and other institutional investors.

CytomX Therapeutics Stock Performance

CTMX stock opened at $4.88 on Wednesday. The firm has a 50 day moving average price of $5.15 and a 200-day moving average price of $3.98. CytomX Therapeutics has a 52-week low of $0.40 and a 52-week high of $6.35. The firm has a market capitalization of $826.82 million, a price-to-earnings ratio of 12.20 and a beta of 2.44.

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.